The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of BXCL701, a novel small molecule inhibitor of dipeptidyl peptidases (DPP), combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC).
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - AstraZeneca; Dendreon; Janssen
Research Funding - Abbvie (Inst); Amgen (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Xynomic Pharma
 
Dan Costin
No Relationships to Disclose
 
Vincent J. O'Neill
Employment - BioXcel Therapeutics
Leadership - BioXcel Therapeutics
Stock and Other Ownership Interests - AstraZeneca; BioXcel Therapeutics; Gilead Sciences; GlaxoSmithKline; Pfizer
Consulting or Advisory Role - Immunome
 
Stefani Corsi-Travali
Employment - BioXcel Therapeutics; Loxo
Stock and Other Ownership Interests - Loxo
 
Sreenivas Adurthi
Employment - BioXcel Therapeutics
 
Adedayo Adedoyin
Employment - BioXcel Therapeutics
Stock and Other Ownership Interests - BioXcel Therapeutics; Merck
 
Diane I. Healey
Employment - BioXcel Therapeutics; Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Pfizer
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Paul Monk
Honoraria - Sanofi/Aventis
Consulting or Advisory Role - Dendreon
Speakers' Bureau - Janssen
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Clovis oncology; Dendreon; Janssen Oncology; Seagen
Speakers' Bureau - Merck Sharp & Dohme; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst)
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Beigene; Fortis; Janssen Oncology; Teon Therapeutics; Tolero Pharmaceuticals
Research Funding - Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Janssen